Results of a year-long drug trial conducted by researchers from UT Southwestern Medical Center show that the experimental drug bardoxolone methyl improves estimated glomerular filtration rates in Type 2 diabetic patients with moderate to severe CKD. Lab tests for those patients revealed decreased blood urea nitrogen, serum phosphorus, uric acid, and magnesium. The new phase 3 trial of bardoxolone is expected to be complete in 2013.
Drug Shows Improved Kidney Function for Patients with Type 2 Diabetes, UT Southwestern Researchers Report, UT Southwestern Medical Center, June 24, 2011
Bardoxolone Improves eGFR Out to One Year in Advanced CKD, By Daniel M. Keller, Ph.D., Renal and Urology News, June 24, 2011